Synthesis of PROTAC-Antibody Conjugate for Application in Acute Myeloid Leukemia Therapy

Project description

A novel targeted anti-cancer therapy

Harnessing the power of the immune system to fight cancer is an attractive therapeutic approach. More specifically, conjugating chemotherapeutic drugs to tumour-specific antibodies improves drug delivery and efficiency while minimising side effects. The EU-funded PAC Synthesis project proposes to combine the advantages of protein degradation and antibody targeting into a new therapeutic platform. Scientists will generate conjugates between proteolysis targeting chimeras (PROTAC) and antibodies targeting the myeloid CD33 protein present in acute myeloid leukaemia cells. The employed chemistry ensures conjugate stability in the blood and efficient release of the PROTAC once internalised by cancer cells.

Fields of science

• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › basic medicine › immunology › immunotherapy
• medical and health sciences › clinical medicine › oncology › leukemia

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Net EU contribution

€ 212 933,76

Address

Trinity Lane The Old Schools
CB2 1TN Cambridge
United Kingdom

Region

East of England › East Anglia › Cambridgeshire CC

Activity type

Higher or Secondary Education Establishments

Links

Non-EU contribution

€ 0,00